• Novasep continues its investment strategy by upgrading its API manufacturing facility at its Mourenx site, increasing its flexibility and competitiveness
• A €6.1 million investment will be made over 3 years
• This investment has been selected by the French Government to be supported by ‘France Relance’, the post-Covid recovery plan
• 7 full-time jobs to be created
Lyon, France – June 24, 2021 - Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce a €6.1 million investment on its Mourenx site (Pyrénées-Atlantiques – France). This investment will modernize its API manufacturing facility, and reinforce its competitiveness in its markets, worldwide.
The modernization of this cGMP workshop includes the installation of new equipment and the revamping of clean rooms for API isolation. This project will enhance Novasep’s flexibility and develop a high-performance capacity for the custom manufacturing of innovative therapeutic molecules, in accordance with the highest quality and safety requirements and with improved environmental protection. To accompany this investment, Novasep also announces the creation of 7 full-time jobs on this site.
This project has been selected as part of the France Relance recovery plan initiated by the French government; Novasep will be supported within the framework of the "Investissements d'Avenir" (Investments for the future) program which rewards innovative and promising industrial investments, in order to allow France to increase its economic growth and employment potential.
“This investment sends a strong signal to our customers and partners by increasing our market competitiveness. It further supports our strategy of reinforcing our high-quality offer for the commercial production of innovative therapies. I am proud of this investment which contributes to manufacturing jobs in France and allows us to further develop our activity in the Aquitaine region” says Dr. Michel Spagnol, Chairman and CEO of Novasep.
Novasep offers flexible contract development & manufacturing (CDMO) solutions for small molecules APIs & biopharmaceuticals to innovators. We propose a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record. We are a world leader in a number of specialized technologies including HPAPIs, ADCs, hazardous & cryogenic chemistry & industrial chromatography (batch and continuous).
+33 4 37 28 20 57
Communication Project Manager